Long-term outcomes after Roux-en-Y gastric bypass: 10- to 13-year data

Obeid, Nabeel R.; Malick, Waqas; Concors, Seth J.; Fielding, George; Kurian, Marina; Ren-Fielding, Christine

doi:10.1016/j.soard.2015.04.011

Cited by 147 publications

(75 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following the introduction of the laparoscopic era, laparoscopic R‐Y gastric bypass (LRYGB) has accelerated the development of both bariatric and metabolic surgery 44. Long‐term (>10 years) weight loss after RYGB was reported to be around 25‐30% total weight loss and 55‐70% excess weight loss ( EWL) 33, 34, 35, 36, 37, 38. Up to 20% of RYGB patients may require revision surgery for various complications or weight regain.…”

Section: New Procedures With Better Outcomesmentioning

confidence: 99%

Recent advancements in bariatric/metabolic surgery

Lee

Almalki

2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Obesity and type 2 diabetes mellitus (T2DM) are currently two pan‐endemic health problems worldwide and are associated with considerable increase in morbidity and mortality. Both diseases are closely related and very difficult to control by current medical treatment, including diet, drug therapy and behavioral modification. Bariatric surgery has proven successful in treating not just obesity but also in significantly decreasing overall obesity‐associated morbidities as well as improving quality of life in severely obese patients (body mass index [BMI] >35 kg/m2). A rapid increase in bariatric surgery started in the 2000s when the laparoscopic surgical technique was introduced into this field. Many new procedures had been developed and changed the face of modern bariatric surgery. Recently, bariatric surgery played as gastrointestinal metabolic surgery has been proposed as a new treatment modality for obesity‐related T2DM for patients with BMI >35 kg/m2. Strong evidence has demonstrated that bariatric/metabolic surgery is an effective and durable treatment for obese T2DM patients. Bariatric/metabolic surgery is now becoming an important surgical division. The present article examines and discusses recent advancements in bariatric/metabolic surgery and covers four major fields: (i) the rapid increase in numbers and better safety; (ii) new procedures with better outcomes; (iii) from bariatric to metabolic surgery; and (iv) understanding the mechanisms and personalized treatment.

show abstract

Section: New Procedures With Better Outcomesmentioning

confidence: 99%

Recent advancements in bariatric/metabolic surgery

Lee

Almalki

2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…It reported a significant reduction in the effectiveness of the second consecutive balloon and no weight loss effect from subsequent balloon placements [15]. After removal of the first balloon (n ¼ 19), %EWL (mean, interquartile ratio [IQR]) was 49 , and TWL (mean, IQR in kilograms) was 15 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) kg. After removal of the second balloon, %EWL dropped to 18 (2.4-42) and TWL to 9.0 (1.0-13) kg.…”

Section: Space-occupying Devicesmentioning

confidence: 99%

“…Given that Roux-en-Y gastric bypass is the gold standard in weight-loss surgery, we compare 5-year weight loss outcomes of Roux-en-Y gastric bypass [20] against those of the ORBERA balloon to contextualize the efficacy of the ORBERA ( F3 Fig. 3).…”

Section: Space-occupying Devicesmentioning

confidence: 99%

“…However, it should be noted that a modification was made to the ReShape Duo device during the trial, and the postmodification ulceration rate was 10% [22]. 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 [20]. For balloon patients, "treatment" refers to device implantation.…”

Section: Space-occupying Devicesmentioning

confidence: 99%

See 1 more Smart Citation

Endoscopic treatments of obesity: a comprehensive review

Neylan

Dempsey

Tewksbury

et al. 2016

Surgery for Obesity and Related Diseases

View full text Add to dashboard Cite

“…I would like to congratulate Obeid et al [1] on their report of long-term outcomes after laparoscopic Roux-en-Y gastric bypass (LRYGB). Obtaining and reporting postoperative outcomes more than 10 years after LRYGB is extremely important, as true long-term results are essential.…”

mentioning

confidence: 99%

Comment on: Long-term outcomes after Roux-en-Y gastric bypass: 10-13 year data

Sundbom

2016

Surgery for Obesity and Related Diseases

View full text Add to dashboard Cite

Long-term outcomes after Roux-en-Y gastric bypass: 10- to 13-year data

Cited by 147 publications

References 31 publications

Recent advancements in bariatric/metabolic surgery

Recent advancements in bariatric/metabolic surgery

Endoscopic treatments of obesity: a comprehensive review

Comment on: Long-term outcomes after Roux-en-Y gastric bypass: 10-13 year data

Contact Info

Product

Resources

About